Imagine a WorldWhere metabolic balance is the norm,And patients live without compromise." We are developing and delivering novel therapies for rare diseases to significantly improve the quality of life for patients and their families. learn more Our lead development program: two Phase 3 programs in congenital and tumor hyperinsulinism. View Our Pipeline Check out stories about how patients and their families address the day-to-day challenges of living with hyperinsulinism. View patient Voices Recent Press Releases view all Rezolute Announces Pricing of Approximately $100 Million Underwritten Offering of Common Stock and Pre-Funded Warrants 11/13/26 Rezolute Announces Positive Results from the Phase 3 upLIFT Study in Tumor Hyperinsulinism 11/13/26 Rezolute Reports First Quarter Fiscal 2027 Financial Results and Provides Business Update 11/05/26
